• Decreased Microvilli Length, and Associated Gene Expression Changes, in Patients With Crohn’s Disease

Decreased Microvilli Length, and Associated Gene Expression Changes, in Patients With Crohn’s Disease

In an analysis of intestinal tissues from patients with Crohn’s disease (CD), researchers identified specific changes in gene expression patterns that associate with histologic changes, such as differences in microvilli length. Decreased microvilli length, via decreased expression of the microvilli gene set, might contribute to epithelial malfunction and the chronic

Read more
  • Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Is it Safe or Effective to Combine Therapies for Inflammatory Bowel Diseases?

Little is known about the efficacy and safety of combination targeted therapy for inflammatory bowel diseases (IBD), despite their use in treatment of other immune-mediated disorders. In a review article in the September issue of Clinical Gastroenterology and Hepatology, Robert P. Hirten et al discuss findings from studies of biologic

Read more
  • 500 Posts by the AGA Journals Blog

500 Posts by the AGA Journals Blog

This week the AGA Journals Blog has reached an important milestone — its 500th post! The blog was started in 2010 to help disseminate the important discoveries published in the AGA Journals to a broader audience. Eight years and over 132,000 views later, it has updated its readers on everything from biomarkers for colon

Read more
  • Does Mucosal Healing Mean Transmural Healing in Children With Crohn’s Disease?

Does Mucosal Healing Mean Transmural Healing in Children With Crohn’s Disease?

 One-third of children with Crohn’s disease have healing in only the mucosa or the bowel wall (not both), researchers report in the July issue of Clinical Gastroenterology and Hepatology. Levels of fecal calprotectin below 300 μg/identify children with mucosal healing. In patients with CD, mucosal healing is associated with reduced risk of relapse,

Read more
  • What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

What Are the Best Endpoints for Trials of Agents for Ulcerative Colitis?

Despite advances in methods of clinical trials for ulcerative colitis (UC), there is still a large amount of variation in endpoints, even in definitions of response and remission, reseachers found in a systematic review published in the May issue of Clinical Gastroenterology and Hepatology. The authors conclude that we need a

Read more
  • What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

What Happens When Patients With Crohn’s Disease in Remission Stop Taking Infliximab?

When patients with Crohn’s disease in sustained remission stopped taking infliximab for a median 7 years, almost one fifth did not require retreatment or have a major complication, researchers report in the February issue of Clinical Gastroenterology and Hepatology. Fewer than one fifth of patients required surgery or developed a complex perianal fistula. Increasing numbers of patients

Read more
  • Are Patients With PSC and Colitis More likely to Have Subclinical Inflammation?

Are Patients With PSC and Colitis More likely to Have Subclinical Inflammation?

Patients with primary sclerosing cholangitis (PSC) and ulcerative colitis (UC) in remission are significantly more likely to have inflammation of the right colon, based on endoscopic and histologic markers, than patients with UC without PSC, researchers report in the January issue of Clinical Gastroenterology and Hepatology. These findings provide insight into cause

Read more
  • Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Does Immunomodulator Therapy for IBD During Pregnancy Affect Newborn Response to Vaccines?

Rates of adequate serologic response to Haemophilus influenzae B (HiB) and tetanus vaccines are similar among infants born to women with inflammatory bowel diseases (IBD) treated with immunomodulator or biologic agents compared to women who did not receive these immunosuppressive drugs during pregnancy, researchers report in the January issue of Clinical Gastroenterology

Read more
  • Which Patients With Flat Low-grade Dysplasia are at High Risk for Colorectal Cancer?

Which Patients With Flat Low-grade Dysplasia are at High Risk for Colorectal Cancer?

Detection of flat low-grade dysplasia (fLGD) and aneuploidy in colon tissues increases risk for high-grade dysplaisa (HGD) or colorectal cancer (CRC) more than 5-fold in patients with inflammatory bowel disease (IBD), researchers report in the December issue of Gastroenterology. Aneuploidy was also detected in almost all cases of flat HGD (fHGD) IBD is a risk

Read more
  • 3-D Imaging of T-cell Localization in Inflamed Colon Tissues

3-D Imaging of T-cell Localization in Inflamed Colon Tissues

Light sheet fluorescence microscopy (LSFM) provides accurate 3-dimensional images of inflammed intestine of mice with colitis, researchers show in a Gastroenterology in Motion article and video in the October issue of Gastroenterology. The authors demonstrate use of the technology to analyze migration of human T cells in colons of mice with colitis. Improved techniques are

Read more